SCHEMBL8466630

SCHEMBL8466630

O=C1CC(C(=O)OCc2ccccc2)O1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 1/20 0.49
FABP7 O15540 1/20 0.48
FABP5 Q01469 1/20 0.48
ALDH1A1 P00352 3/20 0.47
HPGD P15428 1/20 0.46
MAPK1 P28482 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
SLC6A2 P23975 1/20 0.46
SLC6A3 Q01959 1/20 0.46
KMT2A Q03164 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
CASP1 P29466 1/20 0.46
CASP3 P42574 1/20 0.46
CASP7 P55210 1/20 0.46
CASP6 P55212 1/20 0.46
CASP8 Q14790 1/20 0.46
CYP3A4 P08684 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
TSHR P16473 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20054225 0.82 HPGD (0.48) ELANEFABP7FABP5ALDH1A1HPGD
SCHEMBL19749101 0.81 ALDH1A1 (0.52) FABP7FABP5ALDH1A1MAPK1L3MBTL1
SCHEMBL16648788 0.81 ALDH1A1 (0.52) FABP7FABP5ALDH1A1MAPK1L3MBTL1
SCHEMBL29433900 0.81 ALDH1A1 (0.52) FABP7FABP5ALDH1A1MAPK1L3MBTL1
SCHEMBL8761305 0.81 ALDH1A1 (0.45) ELANEALDH1A1MAPK1L3MBTL1SLC6A2
SCHEMBL20253575 0.81 FABP7 (0.46) ELANEFABP7FABP5ALDH1A1HPGD
SCHEMBL6024964 0.81 ELANE (0.45) ELANEFABP7FABP5ALDH1A1HPGD
SCHEMBL6024185 0.81 ELANE (0.45) ELANEFABP7FABP5ALDH1A1HPGD
SCHEMBL26679383 0.81 GAA (0.50) ELANEFABP7FABP5ALDH1A1HPGD
SCHEMBL2023884 0.81 ELANE (0.45) ELANEFABP7FABP5ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117089060-A Initiation/catalyst, preparation method and application thereof, polylactic acid-polymalic acid, preparation method and application thereof 西北工业大学 2023-11-21 CN disclosed
WO-2013019658-A2 SYNTHETIC NANOCARRIERS COMPRISING POLYMERS COMPRISING MULTIPLE IMMUNOMODULATORY AGENTS SELECTA BIOSCIENCES, INC. (US) 2013-02-07 WO disclosed
US-8267990-B2 Controlled degradation of stents ADVANCED CARDIOVASCULAR SYSTEMS, INC. (US) 2012-09-18 US disclosed
US-20110098803-A1 Controlled Degradation Of Stents ADVANCED CARDIOVASCULAR SYSTEMS, INC. (US) 2011-04-28 US disclosed
US-7794495-B2 Controlled degradation of stents ADVANCED CARDIOVASCULAR SYSTEMS, INC. (US) 2010-09-14 US disclosed
US-7557176-B2 Polyhydroxyalkanoic acid having vinyl, ester, carboxyl or sulfonic acid group and producing method therefor CANON KABUSHIKI KAISHA (JP) 2009-07-07 US disclosed
US-7557176-B2 Polyhydroxyalkanoic acid having vinyl, ester, carboxyl or sulfonic acid group and producing method therefor CANON KABUSHIKI KAISHA (JP) 2009-07-07 US disclosed
EP-1758948-B1 POLYHYDROXYALKANOIC ACID HAVING VINYL, ESTER, CARBOXYL OR SULFONIC ACID GROUP AND PRODUCING METHOD THEREFOR CANON KK (JP) 2009-05-13 EP disclosed
US-20080064828-A1 Polyhydroxyalkanoic Acid Having Vinyl, Ester, Carboxyl or Sulfonic Acid Group and Producing Method Therefor CANON KABUSHIKI KAISHA (JP) 2008-03-13 US disclosed
US-20080064828-A1 Polyhydroxyalkanoic Acid Having Vinyl, Ester, Carboxyl or Sulfonic Acid Group and Producing Method Therefor CANON KABUSHIKI KAISHA (JP) 2008-03-13 US disclosed
US-20080015686-A1 Controlled degradation of stents ADVANCED CARDIOVASCULAR SYSTEMS, INC. 2008-01-17 US disclosed
WO-2007005253-A1 BIODEGRADABLE POLYMER FOR COATING ADVANCED CARDIOVASCULAR SYSTEMS, INC. (US) 2007-01-11 WO disclosed
US-20070005130-A1 Biodegradable polymer for coating ADVANCED CARDIOVASCULAR SYSTEMS, INC. 2007-01-04 US disclosed
US-20070005130-A1 Biodegradable polymer for coating ADVANCED CARDIOVASCULAR SYSTEMS, INC. 2007-01-04 US disclosed
US-5977330-A AS HUMECTANTS FOR SKIN AND MUCOUS MEMBRANES; ANTIDEPOSIT AGENTS CIBA SPECIALTY CHEMICALS CORPORATION (US) 1999-11-02 US disclosed
US-5708152-A DERIVATIVES AS HUMECTANTS AND ANTIDEPOSIT AGENTS CIBA SPECIALTY CHEMICALS CORPORATION (US) 1998-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064828-A1 Polyhydroxyalkanoic Acid Having Vinyl, Ester, Carboxyl or Sulfonic Acid Group and Producing Method Therefor FAR1, ACSL4, ACAD11 ELANE 3588/4885FABP7 656/4885FABP5 617/4885
US-20070005130-A1 Biodegradable polymer for coating MAL2, MGAM, CD44 ELANE 933/4885FABP7 1642/4885FABP5 2147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.